| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Theriva Biologics Inc. is a clinical-stage biotechnology firm dedicated to developing novel treatments for conditions with significant unmet medical needs. The company's pipeline features several promising candidates, including SYN-004, which is engineered to break down commonly used intravenous beta-lactam antibiotics in the gastrointestinal tract. This degradation aims to avert microbiome damage, Clostridioides difficile infection (CDI), the overgrowth of harmful organisms, the rise of antimicrobial resistance (AMR), and acute …
Over the last 12 months, insiders at Theriva Biologics, Inc. have bought $0 and sold $0 worth of Theriva Biologics, Inc. stock.
On average, over the past 5 years, insiders at Theriva Biologics, Inc. have bought $159,974 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 14,000 shares for transaction amount of $9,703 was made by SHALLCROSS STEVEN A (CEO and CFO) on 2023‑06‑07.
| 2023-06-07 | SHALLCROSS STEVEN A | CEO and CFO | 14,000 0.2422% | $0.69 | $9,703 | -31.14% | ||
| 2023-06-06 | SHALLCROSS STEVEN A | CEO and CFO | 26,000 0.4106% | $0.63 | $16,453 | -24.34% | ||
| 2023-02-10 | SHALLCROSS STEVEN A | CEO and CFO | 25,000 0.6508% | $1.04 | $26,075 | -41.29% | ||
| 2023-02-02 | SHALLCROSS STEVEN A | CEO and CFO | 25,000 0.5868% | $0.94 | $23,513 | -33.28% | ||
| 2023-01-25 | SHALLCROSS STEVEN A | CEO and CFO | 25,000 0.5447% | $0.87 | $21,825 | -25.71% | ||
| 2023-01-20 | SHALLCROSS STEVEN A | CEO and CFO | 25,000 0.4668% | $0.75 | $18,705 | -16.20% | ||
| 2022-12-29 | SHALLCROSS STEVEN A | CEO and CFO | 100,000 1.0907% | $0.44 | $43,700 | +41.74% |
| SHALLCROSS STEVEN A | CEO and CFO | 250000 0.5447% | $45,500.00 | 7 | 0 | <0.0001% |
$13,664,154 | 40 | -70.35% | $7.05M | |
$812,698 | 12 | -57.09% | $7.89M | |
$4,146,041 | 11 | -40.86% | $8.55M | |
$120,379 | 10 | -24.48% | $7.65M | |
$176,752 | 10 | -28.86% | $6.66M |
| Increased Positions | 15 | +65.22% | 1M | +229.96% |
| Decreased Positions | 10 | -43.48% | 146,492 | -33.52% |
| New Positions | 8 | New | 369,529 | New |
| Sold Out Positions | 6 | Sold Out | 111,080 | Sold Out |
| Total Postitions | 28 | +21.74% | 1M | +196.44% |
| Ikarian Capital, Llc | $31.00 | 0.35% | 120,031 | 0 | 0% | 2025-09-30 |
| Two Sigma Investments, Lp | $16.00 | 0.18% | 61,837 | +61,837 | New | 2025-09-30 |
| Virtu Financial Llc | $9.00 | 0.11% | 36,781 | +2,286 | +6.63% | 2025-09-30 |
| Jane Street Group, Llc | $9.00 | 0.11% | 36,771 | +36,771 | New | 2025-09-30 |
| Boothbay Fund Management, Llc | $9.00 | 0.11% | 35,601 | 0 | 0% | 2025-09-30 |
| Xtx Topco Ltd | $8.00 | 0.1% | 32,899 | +15,712 | +91.42% | 2025-09-30 |
| Geode Capital Management, Llc | $7.00 | 0.08% | 28,209 | +9,608 | +51.65% | 2025-09-30 |
| Two Sigma Advisers, Lp | $7.00 | 0.08% | 27,284 | +27,284 | New | 2025-09-30 |
| Ubs Group Ag | $6.00 | 0.07% | 22,913 | +22,912 | +2.29M% | 2025-09-30 |
| Vanguard Group Inc | $4.00 | 0.05% | 16,382 | +16,382 | New | 2025-09-30 |